EC313

EC313 is a selective progesterone receptor modulator (SPRM) with mixed agonistic/antagonistic properties. It binds to progesterone receptors with high affinity, showing predominantly antagonistic activity (79.1% compared to mifepristone) and minimal agonistic activity (<0.28%). EC313 has been structurally engineered to possess high oral bioavailability and avoid toxicities encountered with other SPRMs, particularly liver toxicity. It has anti-ovulatory activity exceeding that of Ulipristal acetate or Mifepristone, and binds minimally to glucocorticoid receptors (about 6.4% compared to mifepristone). The compound does not bind to estrogen receptors. EC313's specific pharmacodynamic profile makes it a promising candidate for treating uterine fibroids, endometriosis, and other progesterone receptor-dependent gynecological diseases.